A prospective randomized trial: A comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases

Neoplasma

Volumn 60, Issue 3, 2013, Pages 328-333

  Baczyk, M ^a   Milecki, P ^a,b   Pisarek, M ^a   Gut, P ^a   Antczak, A ^a   Hrab, M ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b 1st Radiotherapy Department of Greater Poland Cancer Center ^*  (Poland)

Author keywords

Bone metastases; Isotope therapy; MCRPC; Prostate cancer; Radiotherapy

Indexed keywords

PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; SAMARIUM 153; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; SAMARIUM;

ADULT; AGED; ANALGESIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE METASTASIS; CANCER PAIN; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEVER; FOLLOW UP; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; TOXICITY; VISUAL ANALOG SCALE; BONE TUMOR; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PAIN ASSESSMENT; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGANOPHOSPHORUS COMPOUNDS; PAIN MEASUREMENT; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SAMARIUM;

MLCS; MLOWN;

EID: 84879339020     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_044     Document Type: Article

References (22)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, MURRAY T, THUN MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. http://dx.doi.org/10.3322/CA.2007.0010
2. FERLAY J, AUTIER P, BONIOL M, HEANUE M, COLOMBET M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592. http://dx.doi.org/10.1093/annonc/mdl498
3. CARLIN BI, ANDRIOLE GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-94. http://dx.doi.org/10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q
4. COLEMAN RE. Skeletal complications of malignanc y. Cancer 1997; 80: 1588-94. http://dx.doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G
5. MUNDY GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 8: 584-593.
6. CEYLAN C, KUCUK N, AYATA BS, GUDEN M, ENGIN K. Dosimetric and physical comparison of IMRT and cyberknife plans in the treatment of localized prostate cancer. Rep Pract Oncol Radiother 2010: 15: 181-189. http://dx.doi.org/10.1016/j.rpor.2010.10.003
7. PETRYLAK DP, TANGEN CM, HUSSAIN MH, LARA PN JR, JONES JA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. http://dx.doi.org/10.1056/NEJMoa041318
8. MALMBERG I, PERSSON U, ASK A, TENNVALL J, ABRAHAMSSON PA. Painful bone metastases in hormonerefractory prostate cancer: Economic costs of Strontium-89 and/or external radiotherapy. Urology 1997; 505: 747-753. http://dx.doi.org/10.1016/S0090-4295(97)00326-9
9. QUILTY PM, KIRK D, BOLGER JJ, DEARNALEY DP, LEWINGTON VJ et al. A comparison of the palliative effects of Strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40. http://dx.doi.org/10.1016/0167-8140(94)90411-1
10. SMELAND S, ERIKSTEIN B, AAS M, SKOVLUND E, HESS SL et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys. 2003; 5: 1397-404. http://dx.doi.org/10.1016/S0360-3016(03)00274-8
11. PORTER AT, MCEWAN AJ, POWER JE, REID R, MCGOWAN DG et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-13. http://dx.doi.org/10.1016/0360-3016(93)90309-J
12. PONS F, HERRANZ R, GARCIA A, VIDAL-SICART S, CONILL C et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997; 24: 1210-14. http://dx.doi.org/10.1007/s002590050143
13. SOERDJBALIE-MAIKOE V, PELGER RM, LYCKLAMA A NIJEHOLT GB, ARNDT JW et al. Strontium-89 (Metastron) and the bisphosphonate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med 2002; 29: 494-8. http://dx.doi.org/10.1007/s00259-001-0728-7
14. LAM MG, DE KLERK JM, ZONNENBERG BA. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153 ethylenediaminetetramethylphosphonic acid combined. J Palliat Med 2009; 12: 649-51. http://dx.doi.org/10.1089/jpm.2009.9591
15. RESCHE I, CHATAL JF, PECKING A, ELL P, DUCHESNE G et al. A dose controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33: 1583-91. http://dx.doi.org/10.1016/S0959-8049(97)00155-X
16. ALBERTS AS, SMIT BJ, LOUW WK, VAN RENSBURG AJ, VAN BEEK A et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997; 43: 175-9. http://dx.doi.org/10.1016/S0167-8140(97)01912-9
17. PARKER C, HEINRICH D, O'SULIVAN JM, FOSSA S, CHODACKI A et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castrate-resistant prostate cancer CRPC: A phase III randomized trial (ALSYMPTA). ECCO-ESMO 2011: Abstract, LBA, Stockholm 2011.
18. OOSTERHOF GO, ROBERTS JT, DE REIJKE TM, ENGELHOLM SA, HORENBLAS S et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44: 519-26. http://dx.doi.org/10.1016/S0302-2838(03)00364-6
19. QUILTY PM, KIRK D, BOLGER JJ, DEARNALEY DP, LEWINGTON VJ et al. A comparison of palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994: 31: 33-40. http://dx.doi.org/10.1016/0167-8140(94)90411-1
20. FIZAZI K, SCHER HI, MOLINA A, LOGOTHETIS CJ, CHI KN et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blinded, placebo controlled phase 3 study. Lancet Oncol 2012; 13: 983-992. http://dx.doi.org/10.1016/S1470-2045(12)70379-0
21. PETRYLAK DP, TANGEN CM, HUSSAIN MH, LARA PN, JONES JA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate ca cer. N Engl J Med 2004; 351: 1513-20. http://dx.doi.org/10.1056/NEJMoa041318
22. HOSKIN PJ, STRATFORD MRL, FOLKES LK, REGAN J, YARNOLD JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000; 355: 1428-1429. http://dx.doi.org/10.1016/S0140-6736(00)02144-9